Boots to become first UK pharmacy to privately prescribe cannabis
Boots first UK pharmacy to prescribe cannabis privately

Boots is set to become the first UK high street pharmacy to privately prescribe cannabis flower or oil to patients aged over 25. The move comes through the company's new online SureLeaf service, which will allow clinicians to offer cannabis to people dealing with conditions such as chronic pain, insomnia or anxiety.

Medicinal cannabis was legalised in the UK in 2018, but obtaining it on an NHS prescription has remained difficult. Those who did receive it through the national health service were typically struggling with severe forms of epilepsy, vomiting caused by chemotherapy, or spasms linked to multiple sclerosis.

Eligibility and qualifying conditions

Pain conditions that may make patients eligible include chronic primary and neuropathic pain, fibromyalgia, chronic back or neck pain, osteoarthritis and rheumatoid arthritis. It could also be a treatment option for women with endometriosis-related pelvic pain and for people who suffer from chronic migraines.

Certain stipulations apply. Patients must have tried other traditional forms of treatment for their conditions first, and some underlying health conditions will disqualify them from receiving a prescription. These include psychosis or schizophrenia, bipolar disorder, liver disease and heart problems.

Prescription details and professional views

If a clinician approves a prescription during a video consultation, it will be valid for a period of 28 days, with the lowest dosage costing just under £40.

Thorrun Govind, former chair of the Royal College of Pharmacy, said that for patients who have not responded to conventional treatments, medicinal cannabis could be 'worth exploring'. She added: 'There isn't one universal eligibility checklist for every cannabis-based medicine. It depends on the patient's circumstances, and the clinical judgement of the prescriber.'

Govind also noted that cannabis-based medicines are controlled drugs and prescribing needs to be undertaken responsibly with proper assessment, monitoring and follow up. She described the development as highlighting the changing landscape of pharmacy and the role of community pharmacy in expanding access to healthcare.

Side effects and wider context

Govind explained that cannabis contains several active compounds, including THC and CBD, which can have different effects on the body. Depending on the formulation, cannabis-based medicines may help some patients manage pain, improve sleep or alleviate certain symptoms. However, she stressed that just because something is derived from a plant does not mean it is automatically safe.

Possible side effects include dizziness, drowsiness, impaired concentration, loss of appetite, nausea and diarrhoea. It can also affect mood, causing behavioural changes, feelings of being high, or on the opposite end of the spectrum, paranoia or suicidal thoughts. According to the NHS, it can also affect how other medicines work.

Medical cannabis is already privately accessible in the UK, but only through dedicated private clinics such as Curaleaf Clinic or Releaf UK. Boots will bring these private prescriptions into the mainstream with its SureLeaf service, a specialist doctor-led medical cannabis service for people living with the listed conditions.

The move follows Boots being taken over by Canadian company Whittington Investments, the holding company for the Weston family. Canada liberalised access to medicinal cannabis in 2001, with its legal recreational market set up in 2018.

Jamie Kerruish, chief healthcare officer for Boots, said: 'At Boots, we're committed to making healthcare more accessible and helping people find the right support for their individual needs. Millions of people live with ongoing pain and for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy.'

The company said SureLeaf will give eligible patients the chance to consider cannabis treatment alongside clinical expertise and 'robust ongoing care'. It added: 'Ultimately, it's about helping people explore appropriate options that could help them better manage their symptoms and improve their quality of life.'

Govind said she is supportive of patients having access to this treatment, as long as they treat it as a medicine rather than 'a risk-free alternative or lifestyle product'.